ArticlesCardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
Introduction
Lowering blood pressure in patients with hypertension reduces the risk of cardiovascular events and death,1, 2 but the optimum target blood pressure is unresolved.3, 4, 5, 6 Randomised trials did not show a benefit of blood pressure targets of less than 140/90 mm Hg,7, 8 and post-hoc analyses have suggested that the benefit of blood pressure-lowering treatment might even be reversed below a certain threshold,5, 9, 10, 11, 12, 13, 14, 15, 16 the so-called J-curve phenomenon.9 Conversely, a large meta-analysis of trials that randomly assigned participants to intensive versus less-intensive blood pressure-lowering treatment showed that intensive blood pressure-lowering was associated with decreased cardiovascular events, and the SPRINT trial18 showed that targeting a systolic blood pressure of less than 120 mm Hg in high-risk patients was associated with a reduction in blood pressure-related adverse outcomes, rather favouring a lower is better approach.
These contradictory results leave clinicians with uncertainty as to the optimum blood pressure target in patients treated for hypertension. The concern for a J-curve phenomenon is particularly relevant for cardiac events,10 because the heart is perfused during diastole and its perfusion might be compromised at low diastolic blood pressure values, especially in patients with coronary artery disease, both because a coronary stenosis will lower perfusion pressure in the downstream territory and because autoregulation is altered in these patients.19 Our aim was to study the association between achieved blood pressure levels and cardiovascular outcomes in a large cohort of patients with stable coronary artery disease treated for hypertension from the CLARIFY registry.
Section snippets
Study design and participants
The prospective observational longitudinal registry of patients with stable coronary artery disease (CLARIFY) includes 32 703 outpatients receiving standard care. The registry was observational and did not interfere with clinical management or mandate any test, procedure, or treatment.20 Patients were enrolled in 45 countries (excluding the USA). Eligible patients had stable coronary artery disease, defined as at least one of the following: documented myocardial infarction for more than 3
Results
22 672 adult patients with coronary artery disease and hypertension were included in the analysis. Demographic data and baseline characteristics of the patients, overall and for each 10 mm Hg increment blood pressure subgroup, are given in Table 1, Table 2; baseline drugs are shown in the appendix. Mean age at baseline was 65·2 years, 17 019 (75%) patients were men, and 15 190 (67%) patients were white. Compared with patients with high systolic blood pressure, those with a lower systolic blood
Discussion
This observational study, done in real-life stable patients with coronary artery disease treated for hypertension, shows that low systolic (<120 mm Hg) and low diastolic (<70 mm Hg) blood pressures are associated with an increased risk of cardiovascular events, with a steep J-curve not only for the composite of cardiovascular death, myocardial infarction, or stroke, but also separately for cardiovascular death, all-cause death, myocardial infarction, or hospital admission for heart failure.
Our
References (31)
- et al.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Lancet
(2016) - et al.
Benefits and potential harm of lowering high blood pressure
Lancet
(1987) - et al.
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)
J Am Coll Cardiol
(2012) - et al.
Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population
J Am Coll Cardiol
(2014) - et al.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Lancet
(2016) - et al.
The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?
J Am Coll Cardiol
(2009) External validity of randomised controlled trials: “to whom do the results of this trial apply?”
Lancet
(2005)- et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
Lancet
(1998) - et al.
Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal
Circ Res
(2015) - et al.
Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials
Hypertension
(2016)
SPRINT: what remains unanswered and where do we go from here?
Hypertension
Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement
Hypertension
Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement
Hypertension
Effects of intensive blood-pressure control in type 2 diabetes mellitus
N Engl J Med
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial
Lancet
Cited by (346)
Rationale of treatment recommendations in the 2023 ESH hypertension guidelines
2024, European Journal of Internal MedicineTowards the personalization of septic shock resuscitation: The fundamentals of ANDROMEDA-SHOCK-2 trial
2024, Revista Espanola de Anestesiologia y ReanimacionThe lowest well tolerated blood pressure: A personalized target for all?
2024, European Journal of Internal MedicineAssociation of low diastolic blood pressure with cardiovascular outcomes and all-cause mortality: A meta-analysis
2024, Current Problems in CardiologyExpert consensus on blood pressure management in critically ill patients
2023, Journal of Intensive Medicine